RespireRx Pharmaceuticals Inc (RSPI): Aiming4, If I read between the lines co...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	4
Posts	153
Boards Moderated	0
Alias Born	10/25/2006

K-G

Re: Aiming4 post# 1702

Thursday, 10/26/2006 5:45:03 PM

Thursday, October 26, 2006 5:45:03 PM

Aiming4,
If I read between the lines correctly, Dr. Stoll expects that if there are no additional issues found with CX-717, and the toxicology assessments show a suitable safe dosing range, then they would conduct some TBD AD efficacy tests, the results of which would be available mid-year 2007 at the earliest. He also said he does not expect any AD deals to be made in the absence of solid efficacy data.

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent RSPI News

Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM